Bookmark
Forward
QuickView for teicoplanin (compound)
PubChem Substance
| Name: | Teicoplanin |
|---|---|
| PubChem Substance ID: | 183910 |
| Description: | Glycopeptide antibiotic complex from Actinoplanes teichomyceticus active against gram-positive bacteria. It consists of five major components each with a different fatty acid moiety. |
| Synonyms: |
Teicoplanine [INN-French]; Tecoplanina [INN-Spanish]; Teicoplaninum [INN-Latin]; Antibiotic 8327A; Tecoplaninum [INN-Latin]; 8327A; Teicoplanin; 61036-62-2; Tecoplanine [INN-French]; Teicoplanina [INN-Spanish].
show more » |
DrugBank
Identification
| Name: | Teicoplanin |
|---|---|
| Name (isomeric): | DB06149 |
| Drug Type: | biotech |
| Description: | Glycopeptide antibiotic complex from Actinoplanes teichomyceticus active against gram-positive bacteria. It consists of five major components each with a different fatty acid moiety. |
| Synonyms: |
Antibiotic MDL 507; Teicomycin A2; Antibiotic 8327A; Teichomycin
|
| Brand: | Targocid, Tagocid |
| Category: | Antibacterial Agents, Glycopeptide antibacterials |
| CAS number: | 61036-62-2 |
Pharmacology
| Indication: | For the treatment of bacterial infections caused by susceptible microorganisms. |
|---|---|
| Pharmacology: |
Teicoplanin is an antibiotic used in the prophylaxis and treatment of serious infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. It is a glycopeptide antiobiotic extracted from Actinoplanes teichomyceticus, with a similar spectrum of activity to vancomyc...
show more » |
| Mechanism of Action: | Teicoplanin inhibits peptidoglycan polymerization, resulting in inhibition of bacterial cell wall synthesis and cell death. |
| Absorption: | Teicoplanin is poorly absorbed after oral administration but is 90% bioavailable when administered intramuscularly. |
| Protein binding: | 90% to 95% |
| Biotransformation: | Two metabolites (metabolites 1 and 2; 2 to 3% of total teicoplanin) have been isolated after intravenous administration of radiolabeled teicoplanin. After purification, their structures were found to be new teicoplanin-like molecules, bearing 8-hydroxydecanoic and 9-hydroxydecanoic acyl moieties. This metabolic transformation is likely due to hydroxylation in the omega-2 and omega-1 positions for metabolites 1 and 2, respectively, of the C-10 linear side chain of component A2-3. This might explain the low extent of metabolism of teicoplanin if we consider that only component A2-3 has a linear chain that is susceptible to such oxidation. |
| Half Life: | 70-100 hours |
| Affected organisms: | Gram-positive Bacteria |
Targets
